Godavari Drugs has issued a corrigendum to its earlier intimation regarding the scheduling of its Board Meeting, correcting a typographical error in the proposed date. The company clarified that the Board Meeting, originally misstated as taking place on August 24, 2026, will actually be held on Friday, August 14, 2026. This correction ensures that stakeholders and regulatory bodies are aware of the accurate timeline for the approval of the Un-Audited Financial Results for the first quarter ended June 30, 2026.

The corrigendum was submitted on August 11, 2026, to the General Manager – Listing at the Corporate Relations Department of BSE Limited. The communication references the original intimation letter dated August 10, 2026, which was filed pursuant to Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company attributed the discrepancy to an inadvertent error in the body of the original letter, while noting that the subject line had correctly indicated the August 14 date.

Key Details of the Correction

The following table outlines the specific details of the corrigendum and the associated Board Meeting:

All other contents of the original intimation letter dated August 10, 2026, remain unchanged. The company expressed regret for the inadvertent error and requested that the exchange take the corrigendum on record. The document was signed by Venkatesh Achanta, Company Secretary & Compliance Officer of Godavari Drugs Limited.

What This Means for Shareholders

For investors and analysts tracking Godavari Drugs , this correction confirms that the financial results for Q1FY27 will be discussed and approved earlier than the erroneously stated date. The Board Meeting on August 14, 2026, remains the critical milestone for the release of the quarterly performance metrics, including revenue, net profit, and operational highlights for the period ended June 30, 2026. Stakeholders should monitor official announcements from the company and BSE Limited following this date for the finalized financial data.

Godavari Drugs Limited has closed its trading window for all designated persons and their immediate relatives from July 1, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter ending June 30, 2026. This restriction is implemented to prevent insider trading and ensure market integrity ahead of the quarterly results announcement.

The closure is in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons. All connected persons and their relatives have been advised not to deal in the securities of the company during this period.

The trading window restriction is a standard compliance mechanism adopted by listed companies to prevent the misuse of unpublished price-sensitive information (UPSI). The designated persons include company directors, officers, and other employees who have access to such information.

The unaudited financial results for the quarter ending June 30, 2026, are expected to be announced shortly. The specific date of the result declaration has not been disclosed in the filing, but the trading window will reopen 48 hours after the information is made public.